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AbstrACt
Introduction Chronic kidney disease (CKD) 
management in the UK is usually primary care based, 
with National Institute for Health and Care Excellence 
(NICE) guidelines defining criteria for referral to 
secondary care nephrology services. Estimated 
glomerular filtration rate (eGFR) is commonly used to 
guide timing of referrals and preparation of patients 
approaching renal replacement therapy. However, eGFR 
lacks sensitivity for progression to end-stage renal 
failure; as a consequence, the international guideline 
group, Kidney Disease: Improving Global Outcomes 
has recommended the use of a risk calculator. The 
validated Kidney Failure Risk Equation may enable 
increased precision for the management of patients 
with CKD; however, there is little evidence to date for 
the implication of its use in routine clinical practice. 
This study will aim to determine the impact of the 
Kidney Failure Risk Equation on the redesignation of 
patients with CKD in the UK for referral to secondary 
care, compared with NICE CKD guidance.
Method and analysis This is a cross-sectional 
population-based observational study using The Health 
Improvement Network database to identify the impact 
of risk-based designation for referral into secondary 
care for patients with CKD in the UK. Adult patients 
registered in primary care and active in the database 
within the period 1 January 2016 to 31 March 2017 
with confirmed CKD will be analysed. The proportion 
of patients who meet defined risk thresholds will be 
cross-referenced with the current NICE guideline 
recommendations for referral into secondary care along 
with an evaluation of urinary albumin–creatinine ratio 
monitoring.
Ethics and dissemination Approval was granted by 
The Health Improvement Network Scientific Review 
Committee (Reference number: 18THIN061). Study 
outcomes will inform national and international 
guidelines including the next version of the NICE 
CKD guideline. Dissemination of findings will also 
be through publication in a peer-reviewed journal, 
presentation at conferences and inclusion in the core 
resources of the Think Kidneys programme.
IntroduCtIon
Patients with chronic kidney disease (CKD) 
are routinely managed in primary care, with 
National Institute for Health and Care Excel-
lence (NICE) guidelines defining criteria 
for referral to secondary care nephrology 
services.1 The focus in secondary care is 
strengths and limitations of this study
 ► The Health Improvement Network is a large UK 
primary care electronic medical record resource 
with over 3 million active patients from 787 general 
practices.
 ► Due to laboratory variation in measurements, we 
are standardising estimated glomerular filtration 
rate (eGFR) using the gold-standard Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) 
equation to allow for data comparison; however, 
some laboratories may still report eGFR using the 
Modification of Diet in Renal Disease equation.
 ► The CKD-EPI equation requires knowledge of black 
ethnicity in order to calculate eGFR; if this informa-
tion is not available, it could lead to misclassification 
of patients into stages 3–5 chronic kidney disease 
(CKD); individuals of black ethnicity make up 3.3% 
of the UK population so the consequence of this may 
be limited.
 ► A proportion of people with CKD stages 3–5 will not 
have been tested for urine albumin–creatinine ra-
tio; this group may include patients who meet the 
criteria for referral to nephrology services both by 
the National Institute for Health and Care Excellence 
(NICE) guideline and/or the Kidney Failure Risk 
Equation thresholds, therefore reducing the number 
of the population in the primary analysis.
 ► The NICE criteria for referral into secondary care that 
cannot be assessed comprise hypertension that re-
mains poorly controlled despite the use of at least 
four antihypertensive drugs at therapeutic doses, 
known or suspected rare or genetic causes of CKD 
and suspected renal artery stenosis. 
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primarily on patients with CKD who have progressive or 
advanced disease and where there is perceived to be a 
significant risk of progression to end-stage renal failure.
In England, the estimated prevalence of patients with 
known stage G3a to G5 CKD (estimated glomerular 
filtration rate (eGFR) <60 mL/min/1.73 m2 confirmed 
on retesting) is 5.2%.2 However, only a small proportion 
of these patients need to be followed up in secondary 
care; the large majority are followed up in primary care 
with a monitoring strategy to identify any decline in 
eGFR or increase in proteinuria, usually tested by urine 
albumin–creatinine ratio (ACR). A major consideration 
for primary care is the timing of referral to secondary 
care where patients receive ongoing management of 
CKD progression, treatment for complications of CKD 
and timely preparation of patients for renal replacement 
therapy (RRT).
Patients with advanced CKD in secondary care receive 
information from members of a specialist renal multi-
disciplinary team regarding end-stage renal failure and 
the options for RRT or conservative care. In the UK, the 
number of adult patients initiating RRT in 2015 was 7814, 
equivalent to an incidence rate of 120 per million popula-
tion.3 At present, guidelines recommend ‘timely referral’ 
for planning RRT,4 5 with patients offered information 
tailored to their severity of CKD and the risk of progres-
sion to allow time for them to fully understand and make 
informed choices about their treatment.1 6–9
An area of major concern in CKD practice is the lack 
of precision around the timing of referral to secondary 
care and preparation for end-stage renal failure.10 The 
trajectory of renal disease progression and therefore the 
time to end-stage renal failure varies widely between indi-
viduals.7–9 As a consequence, patients are often uncertain 
how their disease will progress and have described feeling 
unprepared for dialysis therapy.11
Currently, the level of eGFR is the main param-
eter used to guide the timing of referral to secondary 
care nephrology services and preparation for patients 
approaching advanced CKD and RRT.12 The UK Renal 
Association guidelines recommended that ‘most patients 
whose eGFR is <30 mL/min/1.73 m2 and declining 
should receive timely and personalised information 
regarding established kidney failure and RRT options so 
they can make an informed decision about treatment’.6 
This is also the level of renal function at which NICE 
recommends specialist referral.1 However, most patients 
with an eGFR <30 mL/min/1.73 m2 are likely to be at low 
risk (defined as <10%)13 of progressing to RRT in a 2-year 
period. There is large variation in the risk of progression 
to RRT as variables that are independent of the eGFR, 
namely age, gender and urinary ACR are covariates in 
risk of progression.
The lack of sensitivity of eGFR for progression to RRT 
was recognised by Kidney Disease: Improving Global 
Outcomes (KDIGO), which endorsed the use of a vali-
dated risk calculator and suggested referral for planning 
RRT if there is a risk of kidney failure (that may require 
treatment with dialysis or transplantation) of 10%–20% 
or higher within 1 year.4 The Kidney Failure Risk Equa-
tion is a generalisable CKD risk prediction model that 
has been externally validated with patients from over 
30 countries worldwide.13 14 It calculates the 2-year and 
5-year probability of progression to end-stage renal failure 
requiring treatment with dialysis or transplantation for 
a patient with CKD. Work done by a nephrology group 
in Canada, defined a risk-based practice where Kidney 
Failure Risk Equation scores were used to triage refer-
rals into secondary care and to direct patients into the 
appropriate nephrology clinic and services through the 
CKD journey.7 Furthermore, a threshold of a 5-year risk 
to end-stage renal failure of ≥3% for nephrology referral 
has been integrated and evaluated in a Canadian popu-
lation; this has shown to benefit a high-risk population 
by increasing precision in CKD management, including 
reducing wait times for secondary care review.15
Using an eGFR threshold alone, a patient who is at low 
risk for progression may experience premature planning 
for treatment for end-stage renal failure, resulting in 
patient anxiety16 and an unnecessary use of resources.17 
Conversely, patients who are at a higher risk of progres-
sion may not be identified early enough to allow suffi-
cient time for education and intervention to enable 
appropriate dialysis modality decision and access forma-
tion or for transplant suitability assessment and listing. 
For example, using the Kidney Failure Risk Equation, two 
male patients of 50 years of age with an eGFR of 30 mL/
min/1.73 m2 will have a very different risk of progres-
sion to end-stage renal failure when stratified by a urine 
ACR of 1 mg/mmol compared with 300 mg/mmol, with 
respective 2-year and 5-year risks of 1.52% and 18.22% 
and 5.77% and 54.11%, respectively.6
Information provided by the Kidney Failure Risk 
Equation may help to reduce burden for those at low 
risk of progression, guide the timing of information for 
modality planning, improve patient outcomes and offer 
cost savings to the healthcare system through optimising 
the use of resources, creating a more efficient pathway for 
patients with CKD.9 13 Other potential benefits include 
enhancing the accuracy of commissioning and delivery 
of renal services. Most importantly, it may help patients to 
understand the path of their chronic illness and in turn 
allow them to prepare both physically and psychosocially. 
In the UK, the equation is not widely used in routine 
clinical care, and there is little known of the benefits to 
a patient with CKD and the impact on the healthcare 
system of the incorporation of risk prediction into the 
clinical pathway.8 18 19 Further research to evaluate the 
impact of prognostic modelling is required.20
This study will explore the practical application of risk 
prediction to end-stage renal failure in patients with CKD 
by identifying the burden of need in primary care and the 
impact on renal services in the UK if the Kidney Failure 
Risk Equation is implemented. This will be addressed 
by identifying the number of patients who fulfil referral 
criteria from primary to secondary care nephrology 
 o
n
 14 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027315 on 9 June 2019. Downloaded from 
3Bhachu HK, et al. BMJ Open 2019;9:e027315. doi:10.1136/bmjopen-2018-027315
Open access
using current NICE-based criteria, and these data will be 
compared with the number ascertained with the Kidney 
Failure Risk Equation, using risk thresholds for referral 
into secondary care. Results may also guide adjustments 
to predefined thresholds for our UK population.
MEthods And AnAlysIs
study design and data source
This is a cross-sectional population-based observational 
study using The Health Improvement Network (THIN) 
database to identify the impact of risk-based designa-
tion for patients with CKD in the UK. THIN is a large 
UK primary care electronic medical record resource with 
over 3 million active anonymised patients’ data. Patients 
registered in primary care for at least a year and active in 
the THIN database with an index serum creatinine (SCr) 
level within the period 1st January 2016 to 31st March 
2017 will be included in the study.
The Kidney Failure Risk Equation requires four vari-
ables: age, gender, eGFR (calculated from plasma or 
serum creatinine using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation) and 
urine ACR. While CKD-EPI is the recommended creati-
nine-based eGFR equation, many laboratories may still be 
calculating eGFR using the Modification of Diet in Renal 
Disease (MDRD) equation, and subsequent referrals to 
secondary care will be based on this result.Serum creat-
inine (SCr) and ethnicity data, where available, will be 
used in order to recalculate the eGFR using the CKD-EPI 
equation.
The variables available in the THIN database allow 
for integration into the Kidney Failure Risk Equation to 
calculate the proportion of patients who fulfil criteria for 
referral into secondary care nephrology services and will 
be cross-referenced with current NICE guideline referral 
criteria.
data collection
A flow diagram to illustrate the method for data collec-
tion is shown in figure 1. All adults aged 18 years and 
older will be identified. The first SCr from 1 January 
2016 to 31 March 2017 will be collected, and to confirm 
CKD, a second SCr value will be required >90 days from 
the first. The latest of the two SCr values will be the 
index SCr. Using age, gender, ethnicity and SCr data, 
eGFR values will be calculated using the CKD-EPI equa-
tion. Those patients meeting the KDIGO definition of 
CKD, that is, eGFR <60 mL/min/1.73 m2 on at least 
two separate occasions, more than 90 days apart will be 
identified. All individuals who have a urine ACR level 
within 12 months from the index SCr will be included 
in the primary analysis.
With the group of patients identified for the primary 
analysis, we will establish the impact of redesignation of 
referrals to nephrology services using the Kidney Failure 
Risk Equation compared with the current NICE criteria 
using the eGFR by calculating the number of patients 
who meet pragmatic thresholds that are currently in use 
or being proposed including:
1. NICE criteria of referring with1:
a. An eGFR <30 mL/min/1.73 m2.
2. Kidney Failure Risk Equation criteria of:
a. ≥3% risk of end-stage renal failure at 5 years.
b. ≥10% risk of end-stage renal failure at 2 years.
The study will also allow an assessment of the propor-
tion of patients who have available an ACR to allow 
risk stratification and direct management of CKD. The 
current NICE-recommended thresholds for ACR based 
referral into secondary care for a patient with CKD are1:
1. ACR ≥70 mg/mmol, unless known to be caused by dia-
betes and already appropriately treated.
2. ACR ≥30 mg/mmol and haematuria.
For those who have not had their urine ACR meas-
ured, the secondary analysis will establish the number of 
patients who, according to the current NICE CKD guid-
ance, should have their urine ACR measured annually 
if they have an eGFR <60 mL/min/1.73 m2, that is, have 
CKD.1 This group may include patients who meet criteria 
for referral to nephrology services by eGFR and so absence 
of ACR recording will be investigated. Baseline charac-
teristics data and severity of CKD in this group will be 
reviewed and compared with those with their urine ACR 
recorded. Baseline characteristics chosen are consistent 
with NICE CKD guidance, which recommends offering 
testing for CKD using eGFR and/or ACR in people with 
risk factors for CKD.1
Figure 1 Flow diagram to illustrate the method for 
data collection. ACR, albumin–creatinine ratio; CKD, 
chronic kidney disease; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; eGFR, estimated 
glomerular filtration rate; KDIGO, Kidney Disease: Improving 
Global Outcomes; NICE, National Institute for Health and 
Care Excellence; RRT, renal replacement therapy.
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Study inclusion criteria:
 ► Adults aged 18 years and older.
 ► Must have two recorded SCr values at least 90 days 
apart.
Study exclusion criteria:
 ► Patients who are pregnant at time of recorded data.
 ► Patients who have reached end-stage renal failure:
 – On RRT (haemodialysis, peritoneal dialysis or have 
received a renal transplant).
 – eGFR ≤9 mL/min/1.73 m2
 ► Patients with eGFR ≥60 mL/min/1.73 m2.
study variables
Using age (Years), gender, ethnicity (black or Other) and 
the index serum creatinine values (µmol/L), eGFR (mL/
min/1.73 m2) will be calculated using the CKD-EPI equa-
tion. The Kidney Failure Risk Equation requires four vari-
ables: age (years), gender, eGFR (mL/min/1.73 m2) and 
urine ACR (mg/mmol).
Read codes, a set of clinical terms that describe the 
medical history of patients in the THIN database, will be 
used to identify the comorbidity data and allow described 
patients to be excluded from the analysis. Patients who 
reach end-stage renal failure are defined as those who 
have commenced RRT or follow a conservative care (non-
RRT) pathway. Read codes will identify those who are 
pregnant or are receiving RRT (dialysis or renal trans-
plant) at time of data collection enabling their exclu-
sion from the analysis. No clearly defined Read code is 
available for patients on a conservative care pathway so 
patients with an eGFR ≤9 mL/min/1.73 m2, the mean 
eGFR at which a patient with CKD commences RRT in 
the UK,3 will be excluded from the study.
The following baseline characteristics will be collected: 
diabetes, hypertension, acute kidney injury, ischaemic 
heart disease, chronic heart failure, peripheral vascular 
disease, cerebrovascular disease, calcineurin inhibitor 
(tacrolimus and ciclosporin)/lithium use, renal calculi/
prostatic disease, systemic lupus erythematosus and 
haematuria, plus haemoglobin and serum phosphate, 
both measured within 12 months of the SCr.1 21
NICE CKD recommendation advises at least annual 
quantification of urinary albumin or protein loss for 
people with an eGFR <60 mL/min/1.73 m2.1 Evalu-
ation of patients with CKD who have not had an ACR 
measurement within 12 months of the index SCr will 
identify patients who have had their ACR tested greater 
than 1 year from the SCr value or have had alternative 
measurements such as urinalysis, protein:creatinine 
ratio or 24 hours urine protein excretion, investigated 
using available Read codes, within 12 months from the 
index Scr. The proportion of patients who have not 
been tested for urinary albumin or protein loss will be 
calculated.
Analysis
STATA V.14.2 will be used for data collection and anal-
ysis. The number of patients who meet the criteria for 
inclusion into the primary and secondary analyses will be 
identified (see figure 2).
Primary analysis
The proportion of patients meeting the current NICE 
criteria for referral to secondary care nephrology services 
will be compared with the proportion meeting defined 
Kidney Failure Risk Equation thresholds. A net reclassifi-
cation approach will be applied to determine the patients 
reclassified according to risk thresholds. We will estimate 
at which risk threshold equipoise is reached compared 
with current NICE guidelines for referral.
Secondary analysis
The baseline characteristics of those with CKD stage 3–5 
(predialysis) will be described with categorical variables 
as n (%) and numerical data as median (IQR). The differ-
ences will be observed between patients who do and do 
not have a urine ACR documented within 12 months of 
index SCr. Patients without a urine ACR measurement 
within 12 months of the index SCr will be evaluated to 
identify the number and proportion who have had alter-
native measurements of urinary protein loss, measure-
ments of ACR or alternative outside of the specified study 
time criteria and those who have not been checked for 
urinary protein loss.
Patient and public involvement
This study was informed by the Kidney Health Delivering 
Excellence strategy, led by Kidney Care UK, the major UK 
kidney patient charity, which included all relevant UK 
patient-including organisations and developed a strategy 
based on patient and professional dialogue. Included 
within the strategy are the recommendations: ‘(1) 
Figure 2 Study population. ACR, albumin–creatinine ratio; 
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; eGFR, estimated 
glomerular filtration rate; KDIGO, Kidney Disease: Improving 
Global Outcomes; RRT, renal replacement therapy.
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Awareness. of the factors that increased the risk of kidney 
disease…’. This recommendation will be addressed by 
increasing the use of ACR in referral pathways and using 
ACR in risk stratification; ‘(6) Preparation and Choice…
patients approaching end-stage renal disease…are given 
sufficient time and support to prepare for a treatment’. 
This will be addressed by using an approach that iden-
tifies patients with precision for risk to end-stage renal 
disease. In addition to addressing these recommenda-
tions, the study addresses recommendations 15 and 16, 
which specifically deal with research and quality improve-
ment, respectively.22
limitations
Data recorded in the THIN database for eGFR values may 
be calculated locally using the MDRD or CKD-EPI equa-
tions depending on the laboratory. Both NICE guidelines 
and Kidney Failure Risk Equation recommend eGFR 
values using the CKD-EPI creatinine equation as it has 
been shown to more accurately estimate the eGFR and 
classify fewer patients with CKD.23 However, many refer-
rals to secondary care are still based on eGFR laboratory 
values that use the MDRD equation. Therefore, in this 
study, we will collect data to enable calculation of eGFR 
using the CKD-EPI creatinine equation. There may be 
incomplete data due to variables not being recorded. 
Most importantly, ethnicity, in particular black ethnicity, 
is a variable used to calculate the eGFR using the CKD-EPI 
equation. Without this being fully recorded, there may be 
an underestimate of renal function for some patients who 
are of black race but have these data missing, potentially 
leading to an overestimate of patients in stages 3–5 CKD. 
Individuals of black ethnicity make up 3.3% of the UK 
population24 so the consequence of this may be small.
The confines of the data collection from THIN data-
base mean it will be challenging to accurately assess CKD 
progression as defined by the NICE guidelines. There will 
be variation in the timing and number of SCr measure-
ments a patient may have. NICE CKD guidelines recom-
mend a minimum of three eGFR values of a period of not 
less than 90 days, and in people with a new finding of a 
reduced eGFR, it should be repeated within 2 weeks to 
exclude acute decline.1
In patients with CKD and an ACR of 70 mg/mmol or 
more, it may be difficult to identify with certainty if it is 
caused by diabetes and then to assess if the diabetes is 
appropriately treated without review of the individual 
patient. This limitation will be addressed by reporting the 
number of patients with an ACR of 70 mg/mmol or more 
and diabetes but not subdividing the group between 
patients who may or may not have diabetes causing the 
CKD.
The NICE criteria define that patients with CKD 
should be referred for hypertension that remains poorly 
controlled despite the use of at least four antihypertensive 
drugs at therapeutic doses, known or suspected rare or 
genetic causes of CKD or suspected renal artery stenosis. 
In mainstream clinical renal practice, the numbers of 
these patients are likely to be low, and patients currently 
being referred cannot be estimated accurately. THIN 
does not allow for an assessment of this.
NICE CKD recommendations advise at least annual 
quantification of urine albumin or protein loss for 
people with an eGFR <60 mL/min/1.73 m2 with or 
without diabetes and patients with an eGFR of ≥60 mL/
min/1.73 m2 if there is a strong suspicion of CKD.1 The 
National CKD Audit showed there may be a number of 
people who have not been tested for urine ACR with 
stage 3–5 CKD and some general practitioners only send 
urine for ACR testing if the urine dipstick test is posi-
tive.21 Absence of ACR data in patients with CKD as a 
confounding factor will be investigated in this study by 
identifying if they have any ACR measurements outside of 
the specified time criteria or alternative measurements of 
albumin or protein loss such as urinalysis, protein:creat-
inine ratio or 24 hours urine protein excretion within 12 
months of the index SCr. The latter group may include 
patients who meet criteria for referral to nephrology 
services by eGFR and may reveal extra potential patients 
who could have been included in the primary analysis if 
urine ACR was the unit measured instead.
The Kidney Failure Risk Equation uses single-timepoint 
variables to calculate risk and does not take into account 
previous values or changing laboratory test results over 
time.25 A dynamic model compared with a static model 
(eight-variable Kidney Failure Risk Equation) only 
modestly improves the powerful risk prediction of the 
Kidney Failure Risk Equation,25 as demonstrated by the 
C statistic: 0.91 (95% CI 0.89 to 0.93) versus 0.90 (95% CI 
0.88 to 0.92).
dIsCussIon
This study will explore the practical application of risk 
prediction for end-stage renal failure in patients with 
CKD by identifying the burden of need in primary care 
and the impact on renal services in the UK if the Kidney 
Failure Risk Equation is implemented. At present, the 
difference in number of referrals in our UK population 
and the potential redesignation of patients using a risk-
based model is unclear.
To our knowledge, there are no studies on a popula-
tion-based level to assess the impact of criteria for referral 
on clinical outcomes. The current NICE guidelines do 
not map on to long-term clinical outcomes; however, the 
Kidney Failure Risk Equation does; requiring RRT is a 
major clinical end-point associated with high mortality 
and other adverse clinical, patient reported and health 
economic outcomes.
However, to model the impact of the intervention would 
require a step-wedge study in enrolling geographical areas 
with correction for multiple confounders. Assessing the 
current NICE criteria against outcomes is challenging in 
that it would not correct for confounding by factors that are 
common in patients with advanced CKD including frailty. 
However, the Kidney Failure Risk Equation is validated 
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and includes death as a competing risk of progression to 
end-stage renal failure. Ultimately, a study comparing the 
impact of an intervention (referral) against criteria that 
have not been mapped against outcome, with criteria that 
have been mapped against outcome may not be achiev-
able. In resource-limited healthcare systems (all health-
care systems), a starting point is defining the impact at 
a population level of a transition from one system that is 
opinion based (current) to a system that uses a tool that 
has a quantifiable risk of the end-point, which is the ratio-
nale for follow-up in specialist nephrology services; this 
study is designed to do that.
The outcome of this study may direct a potential change 
in CKD management pathways, increasing the preci-
sion with which patients are identified for referral into 
secondary care nephrology services. As a consequence, 
implementing this change will require consideration of 
incorporation of the Kidney Failure Risk Equation into 
clinical informatics systems that will enable close working 
to define appropriate models for delivery of renal services, 
prompt identification of individuals with increased risk of 
progression and produce an increased focus on identifi-
cation of core covariables in particular ACR and ethnicity, 
which are inadequately checked and recorded.21
The health economic impact will need to be explored, 
from requirements for implementing change to cost 
savings with improved efficiency. Delivering a risk-based 
service will require consideration of how patients with 
CKD interpret risk counselling, the optimal method 
of communication of risk, preferences on how and 
when information is shared and training of healthcare 
professionals.
Further research based on the outcome of this study 
will be necessary to establish and assess risk-based renal 
referral and management pathways, investigate appro-
priate incorporation and communication of risk to 
patients, education and training needs of healthcare 
professionals and the health economic impact of inte-
gration of the Kidney Failure Risk Equation into clinical 
practice.
EthICs And dIssEMInAtIon
The outcome of the results to individually risk stratify 
patients with CKD may provide evidence towards a change 
in renal referral pathways. The use of the Kidney Failure 
Risk Equation may identify a more efficient and possibly 
more economical service model. The study outcomes will 
inform national and international guidelines including 
the next version of the NICE CKD guideline. Dissemi-
nation of findings will also be through publication in a 
peer-reviewed journal and presentation at conferences.
study status
Ethics permission has been granted and the data obtained 
for the study. The study is in data checking and analysis 
programming phase, and study finish is scheduled for 
August 2019.
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